ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ALK
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ALK
15
trial(s) found.
NCT06834074
Advanced
Available
Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC (
NVL-655-EAP
)
ALK inhibitor,fourth generation
ALK-positive non-small-cell lung cancer
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (AVAILABLE)
NCT06707610
Advanced
Phase 1
Recruiting
A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors (
ALK202-01
)
anti EGFR/cMET antibody-drug conjugate
+ ALK-202
Cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
NCT06656390
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors (
ALK201-01
)
anti-FGFR2b antibody-drug conjugate
+ ALK-201
Cancer
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
NCT06624059
Curative
Phase 3
Recruiting
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status (
HORIZON-2
)
ALK/RET inhibitor
ALK inhibitor
ALK inhibitor,second generation
Alectinib
Carboplatin
Cisplatin
Pemetrexed
RET inhibitor
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,RET-targeting
cytotoxic chemotherapy
platinum-based antineoplastic agent
+ ALK/RET inhibitor
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06333899
Paed
Phase 1
Not yet recruiting
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion (
TarGeT-L
)
ALK inhibitor,third generation
ROS1 inhibitor
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05987332
Advanced
Phase 2 / Phase 3
Recruiting
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) (
IDE196-002
)
ALK inhibitor,first generation
MET inhibitor,type 1
PKC inhibitor
ROS1 inhibitor
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3181 - Prahran - The Alfred Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05384626
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1) (
NVL-655-01
)
ALK inhibitor,fourth generation
Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05170204
Curative
Phase 3
Recruiting
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (
HORIZON-1
)
ALK/RET inhibitor
ALK inhibitor
ALK inhibitor,second generation
ALK inhibitor,third generation
Alectinib
Durvalumab
Entrectinib
RET inhibitor
ROS1 inhibitor
TRK inhibitor
TRK inhibitor,first generation
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,TRK-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
+ ALK/RET inhibitor
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04774718
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available (
GO42286
)
ALK/RET inhibitor
ALK inhibitor,second generation
Central nervous system cancer
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
NCT04094610
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (
CA127-1029
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Central nervous system cancer
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
+ ALK inhibitor
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT03093116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (
TRIDENT-1
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
SA
5042 - Bedford Park - Flinders Medical Centre
NCT02645149
Advanced
Phase 2
Recruiting
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (
MatchMel
)
ALK/ROS1/IGF1R inhibitor
ALK inhibitor
ALK inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Ceritinib
IGF1R inhibitor
MEK inhibitor
ROS1 inhibitor
Ribociclib
Trametinib
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,IGF1R-targeting
cancer therapy,MEK-targeting
cancer therapy,ROS1-targeting
+ ALK/ROS1/IGF1R inhibitor
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACTRN12623000174684
Advanced
Phase 1
Recruiting
A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer (
APG2449OG101
)
ALK inhibitor,third generation
FAK/ALK/ROS1 inhibitor
FAK inhibitor
anthracycline
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ ALK inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Not yet recruiting (1)
Status unknown (1)
Recruitment Country and State
NSW (14)
VIC (7)
WA (5)
QLD (5)
SA (2)
NZ (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (6)
Phase 2 (1)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (10)
Paed (3)
Curative (2)
Cancer Therapy Class
ALK
87%
ROS1
67%
RET
20%
MET
20%
TRK
20%
PD-1/PD-L1
13%
PKC
13%
MEK
13%
CDK4
13%
CDK6
13%
FGFR
7%
FGFR2
7%
FGFR2b
7%
DPD
7%
orotate phosphoribosyltransferase
7%
CTLA4
7%
PD-1
7%
PD-L1
7%
IGF1R
7%
FAK
7%
ATR
7%
BCR-ABL1
7%
CRAF
7%
EGFR
7%
FLT3
7%
JAK1
7%
JAK2
7%
KIT
7%
PDGFR
7%
PDGFRA
7%
PI3K
7%
RAF
7%
SMO
7%
SRC
7%
VEGFR
7%
YES1
7%
mTOR
7%
mTORC1
7%
mTORC2
7%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
2031 - Randwick - Sydney Children's Hospital (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
4101 - South Brisbane - Queensland Children's Hospital (2)
6009 - Perth - Perth Children's Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2109 - North Ryde - Macquarie University Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3181 - Prahran - The Alfred Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
6009 - Nedlands - One Clinical Research (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Central nervous system cancer
Neurological cancer
Melanoma
Uveal melanoma
ALK fusion-solid tumour
ALK-positive non-small-cell lung cancer
Solid tumour with ongenic fusion
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
Haematological malignancy
Lymphoma
Colorectal cancer
Cutaneous melanoma
Gastrointestinal cancer
Lower gastrointestinal cancer
Skin cancer
Gynaecological cancer
Ovarian cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy